Zobrazeno 1 - 10
of 222
pro vyhledávání: '"Vipul Jairath"'
Autor:
Matheus Cavalcante Franco, Sunguk Jang, Bruno da Costa Martins, Tyler Stevens, Vipul Jairath, Rocio Lopez, John J. Vargo, Alan Barkun, Fauze Maluf-Filho
Publikováno v:
Clinical Endoscopy, Vol 55, Iss 2, Pp 240-247 (2022)
Background/Aims Few studies have measured the accuracy of prognostic scores for upper gastrointestinal bleeding (UGIB) among cancer patients. Thereby, we compared the prognostic scores for predicting major outcomes in cancer patients with UGIB. Secon
Externí odkaz:
https://doaj.org/article/324c0641ea7849d6b856c7d87a2d13e8
Autor:
Jiannan Li, Sinan Lin, Jie Wang, Brian G. Feagan, Minhu Chen, Chenchen Qian, David H. Bruining, Dominik Bettenworth, Vipul Jairath, Florian Rieder, Ren Mao, Stenosis Therapy
Publikováno v:
Physiol Rev
Intestinal fibrosis is considered an inevitable complication of Crohn’s disease (CD) that results in symptoms of obstruction and stricture formation. Endoscopic or surgical treatment is required to treat the majority of patients. Progress in the ma
Autor:
Geert R. D'Haens, Florian Rieder, Rocio Sedano, Tran M Nguyen, Ahmed Almradi, Claire E Parker, Brian G. Feagan, Christopher Ma, Lisa M. Shackelton, William J. Sandborn, Vipul Jairath
Publikováno v:
Inflamm Bowel Dis
Background Several indices exist to measure pouchitis disease activity; however, none are fully validated. As an initial step toward creating a validated instrument, we identified pouchitis disease activity indices, examined their operating propertie
Publikováno v:
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, vol 20, iss 12
Clin Gastroenterol Hepatol
Clin Gastroenterol Hepatol
Background & aimsPatients with Crohn's disease (CD) treated with ustekinumab who experience inadequate response, or loss of response after standard induction and/or maintenance dosing may benefit from dose escalation. We conducted a systematic review
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4c6178ce5b3a9a18fa70971346b665ff
https://escholarship.org/uc/item/270528g4
https://escholarship.org/uc/item/270528g4
Autor:
Ruth Belin, Peter D.R. Higgins, Bruce E. Sands, William J. Sandborn, Debra L. Miller, Fumihito Hirai, Jaroslaw Kierkus, Vipul Jairath, Monika Fischer, Geert R. D'Haens, April N. Naegeli, Laurent Peyrin-Biroulet, Jay Tuttle, Elisa Gomez-Valderas, Paul F. Pollack
Publikováno v:
Gastroenterology, 162(2), 495-508. W.B. Saunders Ltd
Background: Mirikizumab is a humanized monoclonal antibody targeting interleukin 23p19 with demonstrated efficacy in psoriasis and ulcerative colitis. We investigated the safety and efficacy of mirikizumab in patients with moderate-to-severe Crohn's
Autor:
Yiran Zhang, Satimai Aniwan, A Weiss, Gursimran Kochhar, Sunanda V. Kane, Bo Shen, Matthew Bohm, Siddharth Singh, Eugenia Shmidt, Jean-Frederic Colombel, Corey A. Siegel, David Faleck, Edward V. Loftus, James P. Campbell, Mahmoud A. Rahal, Siri Kadire, Ronghui Xu, William J. Sandborn, David Hudesman, Arun Swaminath, Joseph Meserve, Robert Hirten, Vipul Jairath, Ryan C. Ungaro, Bruce E. Sands, Karen Lasch, Jenna L. Koliani-Pace, Brigid S. Boland, Parambir S. Dulai, Dana J. Lukin, Shreya Chablaney, Monika Fischer, Adam Winters, Gloria Tran, Shannon Chang, Sashidhar Varma
Publikováno v:
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, vol 20, iss 1
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, vol 20, iss 1
Background & Aims We aimed to compare safety and effectiveness of vedolizumab to tumor necrosis factor (TNF)-antagonist therapy in ulcerative colitis in routine practice. Methods A multicenter, retrospective, observational cohort study (May 2014 to D
Publikováno v:
Current Treatment Options in Gastroenterology. 19:608-627
Autor:
William J. Sandborn, Geert R. D'Haens, Vipul Jairath, Eileen Crowley, John K MacDonald, Ahmed Almradi, Brian G. Feagan, Malcolm Hogan, Christopher Ma, Guangyong Zou, Rocio Sedano, Siddharth Singh, Jurij Hanzel, Claire E Parker
Publikováno v:
Journal of Crohn's & colitis, 16(5), 717-736. Elsevier
Background Precision in estimating placebo rates is important for clinical trial design. Aim To quantify placebo rates across relevant endpoints in Crohn’s disease [CD] trials and identify the factors influencing these rates in a contemporary meta-
Autor:
Mark E. Baker, Reetesh K. Pai, Paula Borralho, Roger Feakins, Brian G. Feagan, Arne Bokemeyer, William J. Sandborn, Noam Harpaz, Leonardo Guizzetti, Florian Rieder, Rish K. Pai, Marie E. Robert, Amitabh Srivastava, David H. Bruining, Mark A. Valasek, Christophe Rosty, Tran M Nguyen, Gert De Hertogh, Lisa M. Shackelton, Vipul Jairath, Ilyssa O. Gordon, Joel G. Fletcher, Ren Mao, Dominik Bettenworth, Claire E Parker, Robert D. Odze, Jiannan Li
Publikováno v:
Gut
ObjectiveEffective medical therapy and validated trial outcomes are lacking for small bowel Crohn’s disease (CD) strictures. Histopathology of surgically resected specimens is the gold standard for correlation with imaging techniques. However, no v
Autor:
Claire E Parker, Leonardo Guizzetti, Gregory Y. Lauwers, Gert De Hertogh, Paula Borralho Nunes, Mark A. Valasek, Reetesh K. Pai, Rish K. Pai, Robert H. Riddell, Christophe Rosty, Vipul Jairath, Christopher Ma, Roger Feakins, Laurent Peyrin-Biroulet, Ahmed Almradi, Eileen Crowley, Geert R. D'Haens, William J. Sandborn, David F. Schaeffer, Brian G. Feagan, Reena Khanna, Aart Mookhoek, Siddharth Singh
Publikováno v:
Almradi, A, Ma, C, D'Haens, G R, Sandborn, W J, Parker, C E, Guizzetti, L, Borralho Nunes, P, de Hertogh, G, Feakins, R M, Khanna, R, Lauwers, G Y, Mookhoek, A, Pai, R K, Peyrin-Biroulet, L, Riddell, R, Rosty, C, Schaeffer, D F, Valasek, M A, Singh, S, Crowley, E, Feagan, B G, Jairath, V & Pai, R K 2021, ' An expert consensus to standardise the assessment of histological disease activity in Crohn's disease clinical trials ', Alimentary Pharmacology and Therapeutics, vol. 53, no. 7, pp. 784-793 . https://doi.org/10.1111/apt.16248
Alimentary Pharmacology and Therapeutics, 53(7), 784-793
Alimentary Pharmacology and Therapeutics, 53(7), 784-793. Wiley-Blackwell
Alimentary Pharmacology and Therapeutics, 53(7), 784-793
Alimentary Pharmacology and Therapeutics, 53(7), 784-793. Wiley-Blackwell
Background Targeting histological remission or response in Crohn's disease (CD) is not recommended in clinical practice guidelines or as an outcome in clinical trials due to uncertainties regarding index validity and prognostic relevance. Aims To con